Therefore, we assessed whether decreasing negative regulation of the NLRP3 inflammasome activation could attenuate colitis in an animal model by treating DSS-exposed mice with the Cbl inhibitor, hydrocotarnine (Fig. 6a). Here, NLRP3 is linked to colitis.